News | December 24, 2024
BASF sells food and health performance ingredients business to Louis Dreyfus Company
Divestment is part of BASF’s strategic portfolio optimization
Divestment is part of BASF’s strategic portfolio optimization
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Harnessing advanced data analysis for early detection, prevention and better outcomes
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated
